Vanguard CPV
Vanguard CPV
Not authorised
- Canine parvovirus, strain NL-35-D, Live
Product identification
Medicine name:
Vanguard CPV
Active substance:
- Canine parvovirus, strain NL-35-D, Live
Target species:
-
Dog
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Canine parvovirus, strain NL-35-D, Live316228000.00/50% tissue culture infectious dose1.00millilitre(s)
Pharmaceutical form:
-
Solution for injection
Withdrawal period by route of administration:
-
Subcutaneous use
-
Dog
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AD01
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Surrendered
Authorised in:
-
Germany
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
- Zoetis Deutschland GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
- Zoetis Belgium SA
Responsible authority:
- Paul-Ehrlich-Institut
Authorisation number:
- 9a/91
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
German (PDF)
Published on: 9/03/2022
How useful was this page?:
